Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
For example, a study published in JAMA Network Open found that patients lost approximately 5.9% of their body weight at 3 months and 10.9% at 6 months
But if you want FDA-approved medications with full clinical support and insurance navigation, WeightWatchers delivers strong value
Do GLP-1RA have a regulatory effect on microglial antigen presentation and microglial-T cell balance
